CG-105-12 for relapsed/refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have tried at least 3 different cancer treatments, including a proteasome inhibitor (like bortezomib) and an immunomodulatory drug (like lenalidomide), and your cancer got worse or came back.
- Your cancer cells must have a protein called BCMA on their surface (a test can check this).
- You cannot have received CAR-T therapy for multiple myeloma before.
- You need to be in fairly good health overall, with your kidneys, liver, heart, and blood counts working well enough.
- You must not have an active infection that is not under control, or certain other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This trial tests a new type of immune cell therapy called CAR-T that targets a protein called BCMA on myeloma cells. It is for people whose myeloma has come back or not responded to at least three prior treatments, and who cannot have a stem cell transplant.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
Hear when a new Relapsed/Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.